USP22 was initially identified as a member of a so-called "death-from-cancer" gene expression signature, comprising a group of genes whose expression strongly correlated with cancer aggressiveness, poor response to currently used therapies, tumor relapse and diminished patient survival [13]. This evidence concerns the gene USP22 and neoplasm.